T2-High Endotype and Response to Biological Treatments in Patients with Bronchiectasis

支气管扩张 医学 美波利祖马布 内型 苯拉唑马布 呼出气一氧化氮 哮喘 相伴的 内科学 恶化 嗜酸性粒细胞 胃肠病学 免疫学 肺 肺活量测定
作者
Martina Oriano,Andrea Gramegna,Francesco Amati,Alice D’Adda,Michele Gaffuri,Marco Contoli,Francesco Bindo,Edoardo Simonetta,Carlotta Virginia Di Francesco,Martina Santambrogio,Giovanni Sotgiu,Francesco Blasi,Stefano Aliberti
出处
期刊:Biomedicines [Multidisciplinary Digital Publishing Institute]
卷期号:9 (7): 772-772 被引量:66
标识
DOI:10.3390/biomedicines9070772
摘要

Although bronchiectasis pathophysiology has been historically understood around the presence of airway neutrophilic inflammation, recent experiences are consistent with the identification of a type 2 inflammation (T2) high endotype in bronchiectasis. In order to evaluate prevalence and clinical characteristics of bronchiectasis patients with a T2-high endotype and explore their response to biologicals, two studies were carried out. In a cross-sectional study, bronchiectasis adults without asthma underwent clinical, radiological, and microbiological assessment, along with blood eosinophils and oral fractional exhaled nitric oxide (FeNO) evaluation, during stable state. Prevalence and characteristics of patients with a T2- high endotype (defined by the presence of either eosinophils blood count ≥300 cells·µL−1 or oral FeNO ≥ 25 dpp) were reported. A case series of severe asthmatic patients with concomitant bronchiectasis treated with either mepolizumab or benralizumab was evaluated, and patients’ clinical data pre- and post-treatment were analyzed up to 2 years of follow up. Among bronchiectasis patients without asthma enrolled in the cross-sectional study, a T2-high endotype was present in 31% of them. These patients exhibited a more severe disease, high dyspnea severity, low respiratory function, and high impact on quality of life. Among the five patients with severe eosinophilic asthma and concomitant bronchiectasis included in the series, treatment with either mepolizumab or benralizumab significantly reduced the exacerbation rate with an effect that persists for up to 2 years of follow up. If validated across different settings, our data suggest the need to design randomized controlled trials on biological treatments targeting the T2-high endotype in bronchiectasis patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
风吹麦浪的应助被11采纳,获得10
刚刚
科目三的应助被雪白俊驰采纳,获得10
1秒前
懒羊羊完成签到 ,获得积分10
2秒前
啾啾完成签到 ,获得积分10
2秒前
4秒前
sunliyan完成签到,获得积分10
5秒前
完美世界的应助被月桂桂采纳,获得10
5秒前
铜板还太少的应助被牧百川采纳,获得10
8秒前
8秒前
天天完成签到 ,获得积分10
9秒前
头铁老常发布了新的文献求助10
10秒前
10秒前
科研通AI65的应助被BruceZh采纳,获得30
12秒前
12秒前
FelixFelicis发布了新的文献求助10
12秒前
ckyyds完成签到,获得积分10
13秒前
淡然的如冬完成签到,获得积分10
13秒前
蜂蜂完成签到 ,获得积分10
14秒前
14秒前
YY发布了新的文献求助10
14秒前
Ella13完成签到,获得积分10
15秒前
15秒前
15秒前
17秒前
17秒前
铜板还太少的应助被牧百川采纳,获得10
18秒前
Hello的应助被头铁老常采纳,获得10
19秒前
19秒前
xxdwyd完成签到,获得积分10
19秒前
玄牝完成签到,获得积分10
19秒前
20秒前
22秒前
多多完成签到,获得积分10
22秒前
22秒前
24秒前
Maestro_S的应助被Leakki采纳,获得10
24秒前
CZY完成签到 ,获得积分10
24秒前
25秒前
田様的应助被对方正在输入采纳,获得10
25秒前
wangmouse完成签到,获得积分10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183298
求助须知:如何正确求助?哪些是违规求助? 9572606
关于积分的说明 21826444
捐赠科研通 7780272
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558136
邀请新用户注册赠送积分活动 2480259